EFFECTS OF ATORVASTATIN ON NEGATIVE SIGN IN CHRONIC SCHIZOPHRENIA: A DDOUBLE BLIND CLINICAL TRIAL

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SAYYAH MEHDI; BOOSTANI HATAM; ASHRAFPOORI MITRA; PAKSERESHT SIROOS

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Pharmaceutical Research Year:2015 | Volume:14 | Issue:4 Page(s): 1269-1274

Download Full-Text

View:

387

Download:

156

Cites:

Information Journal Paper

Title

EFFECTS OF ATORVASTATIN ON NEGATIVE SIGN IN CHRONIC SCHIZOPHRENIA: A DDOUBLE BLIND CLINICAL TRIAL

Author(s)

SAYYAH MEHDI | BOOSTANI HATAM | ASHRAFPOORI MITRA | PAKSERESHT SIROOS | Issue Writer Certificate

Keywords

SCHIZOPHRENIA

NEGATIVE SIGN

ATORVASTATIN

CLINICAL TRIAL

Abstract

The aim of this study was to evaluate the effects of ATORVASTATIN on negative symptoms in patients with chronic SCHIZOPHRENIA. The study was a prospective, double-blind, 6-week trial. Forty patients participated in the study; 19 patients were assigned to the ATORVASTATIN group as well as 21 patients to the placebo group. For assessing NEGATIVE SIGNs, we used Scale for the Assessment of Negative Symptoms (SANS) in weeks 1st, 3nd, 4th, and 6th. Moreover, patients were randomly assigned to treatment groups with Risperidone (6 mg/day) plus 20 mg ATORVASTATIN or with Risperidone (6 mg/day) plus placebo. Mean scores of Scale for the Assessment of Negative Symptoms (SANS) decreased during the treatment but there was no significant difference between the mean scores of two groups. The result of this trial suggested that ATORVASTATIN can be effective in reducing NEGATIVE SIGN in SCHIZOPHRENIA although further studies seem to be needed.

Cites

No record.

References

Cite

APA: Copy

SAYYAH, MEHDI, BOOSTANI, HATAM, ASHRAFPOORI, MITRA, & PAKSERESHT, SIROOS. (2015). EFFECTS OF ATORVASTATIN ON NEGATIVE SIGN IN CHRONIC SCHIZOPHRENIA: A DDOUBLE BLIND CLINICAL TRIAL. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), 14(4), 1269-1274. SID. https://sid.ir/paper/288389/en

Vancouver: Copy

SAYYAH MEHDI, BOOSTANI HATAM, ASHRAFPOORI MITRA, PAKSERESHT SIROOS. EFFECTS OF ATORVASTATIN ON NEGATIVE SIGN IN CHRONIC SCHIZOPHRENIA: A DDOUBLE BLIND CLINICAL TRIAL. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR)[Internet]. 2015;14(4):1269-1274. Available from: https://sid.ir/paper/288389/en

IEEE: Copy

MEHDI SAYYAH, HATAM BOOSTANI, MITRA ASHRAFPOORI, and SIROOS PAKSERESHT, “EFFECTS OF ATORVASTATIN ON NEGATIVE SIGN IN CHRONIC SCHIZOPHRENIA: A DDOUBLE BLIND CLINICAL TRIAL,” IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH (IJPR), vol. 14, no. 4, pp. 1269–1274, 2015, [Online]. Available: https://sid.ir/paper/288389/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops